NRx subsidiary HOPE Therapeutics acquires minority interest in Cohen & Associates; Dr. Cohen named Medical Director

NRX Pharmaceuticals, Inc.

HOPE Therapeutics acquired strategic minority interest in Rebecca S. Cohen, MD, LLC (Cohen & Associates) of Sarasota, FL, effective Oct 17, 2025.
Dr. Rebecca Cohen appointed Medical Director of HOPE Therapeutics, overseeing medical standards in Florida locations.
Cohen & Associates offers TMS, ketamine, and medication management for depression, PTSD, and CNS disorders.
Immediate expansion planned in Western Florida and Palm Beach.
Acquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.